Luc Furic

The University of Melbourne — Australia

Medicine · Health Sciences

35h-index7.2kcitations123works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(35), Cancer Mechanisms and Therapy(31), RNA Research and Splicing(15), PI3K/AKT/mTOR signaling in cancer(15), RNA modifications and cancer(15)

Publications122 total

CDK9 interacts with a RanGTP-Importin-β complex to regulate erythroid enucleation
Journal of Cell Science·2026
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
The Lancet Oncology·2025· 3 cited
Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells
2025· 1 citedOpen Access
Abstract PR-02: Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance
Cancer Immunology Research·2025
77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial
ESMO Open·2025Open Access
Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia
2025Open Access
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
The Lancet Oncology·2025· 17 cited
The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high <i>MYC</i> malignancies
2025· 3 citedOpen Access
Abstract PR004: Second generation RNA Polymerase I inhibitor PMR-116 targets ribsomal RNA synthesis to potently treat a broad spectrum of malignancies
Molecular Cancer Therapeutics·2024· 1 cited
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&amp;T
Journal of Nuclear Medicine·2024· 23 citedOpen Access
Abstract PR007: Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions
Molecular Cancer Therapeutics·2024
Abstract A006: Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions
Molecular Cancer Therapeutics·2024
Abstract PR005: CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition
Molecular Cancer Therapeutics·2024
Abstract 3326: PMR-116, a second generation RNA Polymerase I inhibitor
Cancer Research·2024
Abstract 5578: Multi-omics approach reveals a SMAD4-deficiency signature, translational reprogramming and synthetic lethality in esophageal adenocarcinom
Cancer Research·2024
Abstract A176: Loss of SMAD4 unleashes mTOR and increases dependency on cap-dependent translation in esophageal tumorigenesis
Molecular Cancer Therapeutics·2023
Abstract PR006: PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer
Cancer Research·2023
Abstract 5614: Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
Cancer Research·2023· 3 cited
Figure S4 from Identification of &lt;i&gt;Pik3ca&lt;/i&gt; Mutation as a Genetic Driver of Prostate Cancer That Cooperates with &lt;i&gt;Pten&lt;/i&gt; Loss to Accelerate Progression and Castration-Resistant Growth
2023Open Access
Figure S6 from Identification of &lt;i&gt;Pik3ca&lt;/i&gt; Mutation as a Genetic Driver of Prostate Cancer That Cooperates with &lt;i&gt;Pten&lt;/i&gt; Loss to Accelerate Progression and Castration-Resistant Growth
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Richard J. Rebello(13), Gail P. Risbridger(13), Ola Larsson(12), Ivan Topisirović(10), Renea A. Taylor(9), Nahum Sonenberg(8), Mitchell G. Lawrence(7), Shahneen Sandhu(7), Arun Azad(7), Luc DesGroseillers(6), Mark Frydenberg(6), Eric Kusnadi(6), Laura H. Porter(5), John Pedersen(5), Richard B. Pearson(5), Ross D. Hannan(5), Louise Kostos(5), James P Buteau(5), Michael S. Hofman(5), Nathaniel Robichaud(4)